Haven't used RiMO Therapeutics yet?
Ask Trustburn

Ask Trustburn about RiMO Therapeutics

Based on 12 reviews on Trustburn

Based on reviews on this page. Verify anything important with the company directly.

Irma Verastegui
Reviews 1

RiMO Therapeutics is an amazing company to work with. They have a dedicated team that is always ready to assist with any queries. The quality of their products is top-notch and has helped many patients. I highly recommend them!

Brian Kerr
Reviews 1

I recently came across a company that provides excellent therapeutic solutions. Their website, rimorx.com, showcases a wide range of products. The team is knowledgeable and always happy to answer questions. I've had a positive experience with their treatments.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="rimorx-com" data-lang="en"></div>
More widgets

About RiMO Therapeutics

RiMO Therapeutics, Inc. (RiMO), is a privately held oncology drug development company that aims to address unmet medical needs and improve patient care. Our proprietary Radio-immuno Metal-Organic (RiMO) technology platform greatly enhances the efficacy of X-ray radiotherapy via the unprecedented radiotherapy-radiodynamic therapy (RT-RDT) mode of action. RiMO clinical candidates are intrinsically non-toxic and greatly reduce X-ray doses needed to eradicate local tumors in mouse models. The RiMO technology also allows to combine multiple therapeutic modalities to increase efficacy while simultaneously reducing toxicity.
The RiMO platform was pioneered in the lab of Professor Wenbin Lin at the University of Chicago. As a versatile technology platform, RiMO components can be purposefully chosen to enhance and synergize with currently existing therapies. RiMO products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.

Website
rimorx.com